Melanoma/Skin Cancer News

Researchers identified a gene signature that can predict which group of patients with melanoma will experience severe immune-related adverse events when treated with immune checkpoint inhibitor therapy, according to a study.

The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with relapsed or refractory cutaneous T-cell lymphoma.

In this video, Hansa Bhargava, MD, and Victoria Barbosa, MD, MPH, MBA, FAAD, discuss the impact of UV rays on aging and the risk for skin cancer, as well as ways to protect your skin from the sun.

An immunotherapy combination improved outcomes compared with historical control for certain patients with advanced melanoma, according to a topline data announcement.

Topically applied nanoparticle-encapsulated cannabidiol cream helped prevent and repair damage to the skin from ultraviolet A radiation, according to a first-of-its-kind study.

The Dermatology Association of Radiation Therapy has announced new guidelines for the treatment of nonmelanoma skin cancer, according to an association press release.

About 40% of cancer cases and nearly half of cancer deaths among U.S. adults aged 30 years or older can be attributable to modifiable risk factors, according to a study led by American Cancer Society researchers.

Patients with rosacea have an increased risk for malignant melanoma, joint problems, metabolic disease and visual disturbances, according to a study.

Iovance Biotherapeutics has submitted a marketing authorization application to the European Medicines Agency for lifileucel to treat advanced melanoma, the company announced in a press release.

Rural populations, especially those with skin of color, experience higher prevalence and an increased risk for skin cancer, according to a study.